The CurePSP Genetics Program

Summary

This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families. Up to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• PSP
• PSP - Progressive Supranuclear Palsy
• Corticobasal Syndrome
• Corticobasal Syndrome(CBS)
• Corticobasal Degeneration Syndrome
• Corticobasal Degeneration
• Corticobasal Degeneration (CBD)
• Corticobasal Syndrome (CBS)
• MSA
• MSA - Multiple System Atrophy
• MSA-C
• Multiple System Atrophy
• Multiple System Atrophy (MSA) With Orthostatic Hypotension
• Multiple System Atrophy - Cerebellar Subtype (MSA-C)
• Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
• Multiple System Atrophy, Cerebellar Type
• Multiple System Atrophy, Parkinsonian Type
• Progressive Supranuclear Palsy
• Progressive Supranuclear Palsy(PSP)
• Progressive Supranuclear Palsy (PSP)

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

35 years and older

Sex

All

Healthy volunteers

Accepted

Sponsor

Massachusetts General Hospital

Last updated on ClinicalTrials.gov

January 14, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites